CORPORATE MEDIA RELEASE - NORGINE EXPANDS ITS PARTNERSHIP WITH NOVENTURE TO COMMERCIALISE GELSECTAN® IN FRANCE
Amsterdam. March 5th 2019. Norgine B.V. today announced that it has expanded its partnership with Noventure S.L. by entering into an exclusive distribution agreement for GELSECTAN® in France. This deal expands on Norgine’s existing collaboration with Noventure S.L. under which Norgine distributes GELSECTAN® in Portugal, Spain, Andorra and the Italian Republic (incl. Vatican City and San Marino).
GELSECTAN ® is a Class IIa CE marked medical device used as a treatment for irritable bowel syndrome (IBS) with diarrhoea (IBS-D). IBS is a chronic bowel problem, characterized by abdominal pain, bloating, and changes in bowel habit. 1 Diarrhoea is one of the symptoms often associated with irritable bowel syndrome. GELSECTAN® is available in capsules for oral use.
